Loading cancer entity…
Loading cancer entity…
Clinical trials
8,120 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,290)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04432506 | Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma | completed | Phase 2 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2025 | clinicaltrials |
| NCT03220035 | Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 2 | Jan 27, 2025 |
| clinicaltrials |
| NCT04716075 | Acalabrutinib in CLL and MCL Patients Subjected to Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT)(ACALLO) | completed | Phase 2 | 29 | Polish Lymphoma Research GroupNETWORK | 1 | Jan 16, 2025 | clinicaltrials |
| NCT03773107 | LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 12 | Wake Forest University Health SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT02207062 | Ibrutinib in Treating Patients With Relapsed or Refractory Transformed Indolent B-cell Non-Hodgkin Lymphoma | completed | Phase 2 | 20 | University of WashingtonOTHER | 1 | Jan 7, 2025 | clinicaltrials |
| NCT03484702 | Trial to Determine the Efficacy and Safety of JCAR017 in Adult Participants With Aggressive B-Cell Non-Hodgkin Lymphoma(TRANSCENDWORLD) | completed | Phase 2 | 113 | CelgeneINDUSTRY | 11 | Dec 27, 2024 | clinicaltrials |
| NCT03997968 | A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 169 | Cyteir Therapeutics, Inc.INDUSTRY | 1 | Dec 24, 2024 | clinicaltrials |
| NCT01903811 | S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory Myeloma | completed | Phase 2 | 143 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 20, 2024 | clinicaltrials |
| NCT03677141 | A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma | completed | Phase 1 / Phase 2 | 117 | Hoffmann-La RocheINDUSTRY | 6 | Dec 18, 2024 | clinicaltrials |
| NCT00965224 | Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma | completed | Phase 2 | 38 | Zwi BernemanOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03129828 | Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2(ImbruVeRCHOP) | completed | Phase 1 / Phase 2 | 38 | Prof. Dr. Clemens SchmittOTHER | 1 | Dec 13, 2024 | clinicaltrials |
| NCT03233204 | Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) | completed | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2024 | clinicaltrials |
| NCT01919619 | Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies | completed | Phase 2 | 41 | M.D. Anderson Cancer CenterOTHER | 1 | Dec 3, 2024 | clinicaltrials |
| NCT04436029 | Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy | completed | Phase 2 | 5 | Cartesian TherapeuticsINDUSTRY | 1 | Dec 3, 2024 | clinicaltrials |
| NCT03664635 | MB-CART20.1 Lymphoma | completed | Phase 1 / Phase 2 | 10 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT03233776 | Anakinra: Safety and Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT(AFFECT-1) | completed | Phase 2 | 9 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT04099901 | Anakinra: Efficacy in the Management of Fever During Neutropenia and Mucositis in ASCT - A Randomized Controlled Trial(AFFECT-2) | completed | Phase 2 | 88 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT01857115 | Study of Weekly Carfilzomib, Cyclophosphamide and Dexamethasone In Newly Diagnosed Multiple Myeloma Patients (wCCyd)(wCCyd) | completed | Phase 1 / Phase 2 | 63 | European Myeloma Network B.V.NETWORK | 1 | Nov 13, 2024 | clinicaltrials |
| NCT05269940 | A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies | completed | Phase 1 / Phase 2 | 40 | Nanjing Zenshine PharmaceuticalsINDUSTRY | 1 | Nov 13, 2024 | clinicaltrials |
| NCT00482261 | A Study of Low Dose Lenalidomide and Dexamethasone in Relapsed/Refractory Myeloma in Patients at High Risk for Myelosuppression | completed | Phase 2 | 150 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT01755975 | Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma | completed | Phase 1 / Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT03630042 | Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia(PembroWM) | completed | Phase 2 | 17 | University College, LondonOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT04101331 | Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides(REDIRECT) | completed | Phase 2 | 108 | Affimed GmbHINDUSTRY | 10 | Nov 5, 2024 | clinicaltrials |
| NCT03586999 | Nivolumab With Standard of Care Chemotherapy for Peripheral T Cell Lymphomas | completed | Phase 1 / Phase 2 | 18 | University of Colorado, DenverOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT03145064 | Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell Lymphoma | completed | Phase 2 | 41 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03206970 | Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL) | completed | Phase 2 | 86 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03332173 | Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM) | completed | Phase 2 | 44 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03493451 | Study of BGB-A317 in Participants With Relapsed or Refractory Mature T- and NK-cell Neoplasms | completed | Phase 2 | 77 | BeiGeneINDUSTRY | 5 | Oct 26, 2024 | clinicaltrials |
| NCT03520920 | BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) | completed | Phase 2 | 41 | BeiGeneINDUSTRY | 1 | Oct 26, 2024 | clinicaltrials |
| NCT03846427 | Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma(MAGNOLIA) | completed | Phase 2 | 68 | BeiGeneINDUSTRY | 9 | Oct 26, 2024 | clinicaltrials |
| NCT00285259 | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | completed | Phase 2 | 112 | Astellas Pharma IncINDUSTRY | 1 | Oct 21, 2024 | clinicaltrials |
| NCT02927964 | TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma | completed | Phase 1 / Phase 2 | 21 | Robert LowskyOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT02692248 | Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCT | completed | Phase 2 | 64 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT00747123 | A Safety, Tolerability and Efficacy Study of ACE-011 in Patients With Osteolytic Lesions of Multiple Myeloma | completed | Phase 2 | 30 | CelgeneINDUSTRY | 1 | Oct 3, 2024 | clinicaltrials |
| NCT02375555 | Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM | completed | Phase 2 | 40 | Dana-Farber Cancer InstituteOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT03788291 | Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma | completed | Phase 2 | 39 | University of RochesterOTHER | 1 | Sep 26, 2024 | clinicaltrials |
| NCT02532257 | Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma | completed | Phase 2 | 48 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 24, 2024 | clinicaltrials |
| NCT01827137 | WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 20 | Sellas Life Sciences GroupINDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02633059 | Idasanutlin, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 33 | Mayo ClinicOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT02953652 | Efficacy and Safety of Oral HBI-8000 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) | completed | Phase 2 | 55 | HUYABIO International, LLC.INDUSTRY | 2 | Sep 19, 2024 | clinicaltrials |
| NCT04038359 | A Phase 2 Study Comparing 2 Intermittent Dosing Schedules of Duvelisib in Participants With Indolent Non-Hodgkin Lymphoma(TEMPO) | completed | Phase 2 | 103 | SecuraBioINDUSTRY | 8 | Sep 19, 2024 | clinicaltrials |
| NCT05199337 | Phase 1/2 Study of ZN-d5 for the Treatment of Relapsed or Refractory Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 18 | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.INDUSTRY | 7 | Sep 19, 2024 | clinicaltrials |
| NCT03267888 | Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 25 | Emory UniversityOTHER | 1 | Sep 4, 2024 | clinicaltrials |
| NCT02633137 | Sequential Chemotherapy and Lenalidomide Followed by Rituximab and Lenalidomide Maintenance for Untreated Mantle Cell Lymphoma | completed | Phase 2 | 49 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2024 | clinicaltrials |
| NCT02953301 | Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS)(RESMAIN) | completed | Phase 2 | 201 | 4SC AGINDUSTRY | 12 | Aug 30, 2024 | clinicaltrials |
| NCT04847050 | A Trial of the Safety and Immunogenicity of the COVID-19 Vaccine (mRNA-1273) in Participants With Hematologic Malignancies and Various Regimens of Immunosuppression, and in Participants With Solid Tumors on PD1/PDL1 Inhibitor Therapy | completed | Phase 2 | 19 | National Cancer Institute (NCI)NIH | 1 | Aug 27, 2024 | clinicaltrials |
| NCT02157181 | Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab | completed | Phase 2 | 89 | Jurgen BarthOTHER | 1 | Aug 22, 2024 | clinicaltrials |
| NCT01183949 | Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma | completed | Phase 1 / Phase 2 | 18 | Astex Pharmaceuticals, Inc.INDUSTRY | 1 | Aug 2, 2024 | clinicaltrials |
| NCT02507336 | Long-Term Followup and/or Thalidomide Maintenance Therapy for Patients Enrolled on Clinical Trial 20030165 | completed | Phase 2 | 2 | University of MiamiOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06454266 | First-line Treatment of PCNSL With the Combination of Orelabrutinib, Rituximab, and Methotrexate (ORM Regimen) | completed | Phase 2 | 22 | Ningbo No. 1 HospitalOTHER | 1 | Jul 30, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Jan 28, 2025source: clinicaltrials